Personalized Therapeutics at IU (Sep 4, 2008 10:03)
In August 2008, the Indiana University Department of Medicine’s Division of Clinical Pharmacology began a new series of compelling seminars that may be of great interest to those involved in predictive health research ethics. The Personalized Therapeutics Seminar series commenced on August 5th with a presentation on the FDA’s Sentinel System for Post-market Drug Safety Surveillance given by Barbara Evans, J.D., Ph.D. from the Health Law and Policy Institute at the University of Houston Law Center. Additional speakers this fall, all from the Indiana University School of Medicine, have included Dr. Noah Hahn presenting on the Indiana University Cancer Biomarker Study, Dr. David Haas addressing PREGMED and the search for individualized pharmacotherapy in pregnancy, Dr. Zeruesenay speaking about emerging in vivo phenotyping methods and Dr. Tatiana Foroud addressing the results of whole genome association studies and how they may change our approach to medicine. The next seminar, entitl..
Dr. Margaret M. Gaffney on Professionalism (Aug 13, 2008 09:04)
When: Fri Aug 22, 2008 5:30pm to 6:30pm EDT Where: Lilly Auditorium - University Library Event Status: confirmed Event Description: School of Health and Rehabilitation Sciences New Student Convocation Keynote Speaker: Dr. Margaret M. Gaffney, Faculty Investigator, IU School of Medicine, IU Center for Bioethics
Professional Ethics with Dr. Margaret Gaffney (Aug 13, 2008 08:50)
When: Wed Aug 20, 2008 8:30am to 12pm EDT Where: Executive Education Program ~ SPEA Building - Room 4095 Event Status: confirmed Event Description: Presented by: Margaret M. Gaffney, MD Faculty Investigator IU Center for Bioethics
Medical Records, Insurance and Prediction: GINA Will Not Keep this Fox Out of the Henhouse (Aug 8, 2008 11:04)
In a recent Washington Post article (4 August 2008), " Prescription Data Used to Access Consumers ", Ellen Nakashima writes about the availability of medical records for data mining. Insurance companies have begun to use databases of prescription records to assess the risks of insuring individuals or when deciding to pay for a treatment. For example, a report could show that an "individual has been on the highest does of the cholesterol-reducing drug Zocor for 18 months" and an insurance company could determine that the patient has "a very high, near-intractable cholesterol problem … and could avoid a costly blood test". The article also points out that these records are more honest than many applicants for insurance and could reduce the cost of insurance while facilitating faster decision making. While HIPAA stipulates that patient consent must be acquired before these records can be accessed, "HIPAA does not give the Department of Health and Human Services the ability to directly i..
PredictER Year-End Review (Aug 1, 2008 11:21)
Join us Monday afternoon (August 4th, 3-4pm) at the Center for Bioethics for a year-end review of PredictER's progress. PredictER's director, Eric M. Meslin, will share his assessment of the program's accomplishments and goals for the coming year. This is an excellent opportunity to learn about the services we provide to our constituents with an interest in predictive health research, medicine, and the associated ethical and legal issues. Refreshments will be served. IU Center for Bioethics, 410 W 10th Street, Suite 3100. Indianapolis, IN 46202 | 317-278-4034
Bioethics Journal Club (Jul 30, 2008 10:47)
Recurring Event First start: 2008-09-03 16:00:00 EDT Duration: 3600 Except on: Wed Jan 7, 2009 Where: IUCB, HITS Building, Suite 3100 - Large Conference Room Event Status: confirmed
What's in Steve Jobs's Genome? Genetic Information at the Top (Jul 29, 2008 14:06)
Jacob Goldstein of The Wall Street Journal's Health Blog asks "Do Apple Investors Have Right to Steve Jobs's Health Info?" -- Investing is a gamble and gamblers need good information to make the best bets. Publicly traded companies are required (with varied levels of success) by the SEC to be transparent with their books. So, if you're thinking about investing in a company with a very charismatic CEO, you might want to know about the results of his most recent physical exam. As genomic medicine improves one could imagine a future in which "reasonable" investors demand a genome profile too. Goldstein observes that Jobs is both a "swashbuckling entrepreneur" and a pancreatic cancer survivor. I'm unsure how that information would help an investor and I'm fairly certain the science of reading the genomic tea leaves would not be much help, at least not yet.
PREGMED: Searching for Individualized Pharmacotherapy in Pregnancy (Jul 17, 2008 13:23)
When: Tue Aug 19, 2008 12pm to 1pm EDT Who: PredictER Where: Conference Room W7120 (Wishard Myers Building (WD), 7th Floor). Event Status: confirmed Event Description: David M. Haas, MD Assistant Professor Obstetrics and Gynecology
FDA's Sentinel System for Post-market Drug Safety Surveillance (Jul 17, 2008 13:18)
When: Tue Aug 5, 2008 12pm to 1pm EDT Where: Conference Room W7120 (Wishard Myers Building (WD), 7th Floor). Event Status: confirmed Event Description: Speaker: Barbara Evans JD, PhD Associate Professor Co-director, Health Law & Policy Institute Director, Center on Biotech University of Houston Law Center
"If personalized medicine is the answer, then what’s the question? What pharmacogenomics may tell us about the ethics of medicine and research" (Jul 17, 2008 13:12)
When: Tue Sep 30, 2008 12pm to 1pm EDT Who: PredictER Where: Conference Room W7120 (Wishard Myers Building (WD), 7th Floor). Event Status: confirmed Event Description: Speaker: Eric M. Meslin, PhD Director, Indiana University Center for Bioethics Assistant Dean, Bioethics Professor of Medicine and Medical and Molecular Genetics
